Saxagliptin (Onglyza) indicated in patients with type 2 diabetes mellitus to improve glycemic control in combination with metformin and a sulfonylurea when dual therapy with these two agents, with diet and exercise, does not provide adequate glycemic control
Saxagliptin (Onglyza) is an oral antihyperglycemic agent belonging to the dipeptidyl peptidase-4 (DPP-4) inhibitor class. Saxagliptin is indicated for patients with type 2 diabetes mellitus to improve glycemic control in combination with metformin, a sulfonylurea, metformin and a sulfonylurea, or lo...
Corporate Author: | |
---|---|
Format: | eBook |
Language: | English |
Published: |
Ottawa (ON)
Canadian Agency for Drugs and Technologies in Health
2013, 2013
|
Series: | Common drug review clinical review report
|
Subjects: | |
Online Access: | |
Collection: | National Center for Biotechnology Information - Collection details see MPG.ReNa |
Summary: | Saxagliptin (Onglyza) is an oral antihyperglycemic agent belonging to the dipeptidyl peptidase-4 (DPP-4) inhibitor class. Saxagliptin is indicated for patients with type 2 diabetes mellitus to improve glycemic control in combination with metformin, a sulfonylurea, metformin and a sulfonylurea, or long- or intermediate-acting insulin (with or without metformin), when these drugs do not provide adequate glycemic control. The recommended dose of saxagliptin is 5 mg once daily for most patients and 2.5 mg once daily for patients with moderate or severe renal impairment (creatinine clearance [CrCl] d 50 mL/min). The current Common Drug Review (CDR) submission for saxagliptin is for the manufacturer's requested listed criterion of use in combination with metformin and a sulfonylurea for patients with inadequate glycemic control and for whom insulin is not an option |
---|---|
Item Description: | Title from Web page |
Physical Description: | 1 online resource illustrations |